文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

非奈利酮治疗1型糖尿病合并慢性肾脏病

Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
PubMed 文献 · N Engl J Med · 2026-01-01
一句话结论在1型糖尿病合并CKD成人中,非奈利酮治疗6个月使尿白蛋白肌酐比较安慰剂额外降低25%(几何均值比0.75,95%CI 0.65–0.87,P<0.001)。

该3期试验纳入242例1型糖尿病合并CKD(eGFR 25至<90 ml/min/1.73m²)且尿白蛋白肌酐比200至<5000的成人,均在接受ACE抑制剂或ARB治疗。参与者随机接受非奈利酮(每日10或20 mg,依eGFR决定)或匹配安慰剂。主要终点为6个月内尿白蛋白肌酐比的相对变化,非奈利酮组降低34%,安慰剂组降低12%,组间几何均值比0.75(95%CI 0.65–0.87,P<0.001),提示非奈利酮较安慰剂额外降低25%。最常见不良事件为高钾血症(非奈利酮组12例[10.1%] vs 安慰剂组4例[3.3%]),2例(1.7%)因高钾血症停用非奈利酮;6个月时eGFR变化非奈利酮组-5.6 vs 安慰剂组-2.7 ml/min/1.73m²(差值-2.9,95%CI -5.1至-0.7),洗脱期eGFR接近基线。

要点

  • 非奈利酮组6个月尿白蛋白肌酐比降低34%(几何均值比0.66,95%CI 0.60–0.73),安慰剂组降低12%(0.88,95%CI 0.79–0.98)。
  • 非奈利酮较安慰剂额外降低尿白蛋白肌酐比25%(几何均值比0.75,95%CI 0.65–0.87,P<0.001)。
  • 高钾血症发生率非奈利酮组10.1%(12例)vs 安慰剂组3.3%(4例),2例(1.7%)因高钾血症停用非奈利酮。
  • 6个月eGFR变化非奈利酮组-5.6 vs 安慰剂组-2.7 ml/min/1.73m²(差值-2.9,95%CI -5.1至-0.7),洗脱期eGFR接近基线。
  • 研究纳入eGFR 25至<90 ml/min/1.73m²且尿白蛋白肌酐比200至<5000、已用ACE抑制剂或ARB的1型糖尿病合并CKD成人。

适用人群与场景

  • 成人1型糖尿病合并慢性肾脏病,eGFR 25至<90 ml/min/1.73m²,尿白蛋白肌酐比200至<5000(白蛋白单位mg、肌酐单位g),且正在接受ACE抑制剂或ARB治疗。

诊断标准与关键阈值

  • 慢性肾脏病诊断依据eGFR 25至<90 ml/min/1.73m²且尿白蛋白肌酐比200至<5000。
  • 非奈利酮剂量根据eGFR选择每日10或20 mg。

处置流程与药物剂量

  • 非奈利酮每日10或20 mg(依eGFR决定),口服,疗程6个月;对照为匹配安慰剂。
  • 所有参与者均接受ACE抑制剂或ARB背景治疗。

红旗征与不能漏的情况

  • 高钾血症:非奈利酮组12例(10.1%)vs 安慰剂组4例(3.3%),2例(1.7%)因高钾血症停用非奈利酮。
  • eGFR下降:6个月时非奈利酮组eGFR变化-5.6 ml/min/1.73m²,安慰剂组-2.7 ml/min/1.73m²(差值-2.9,95%CI -5.1至-0.7),洗脱期eGFR接近基线。

研究设计与关键结果

  • 3期随机对照试验,242例参与者随机分配,非奈利酮组与安慰剂组比较。
  • 主要终点:6个月尿白蛋白肌酐比相对变化,非奈利酮组降低34%(几何均值比0.66,95%CI 0.60–0.73),安慰剂组降低12%(0.88,95%CI 0.79–0.98);组间几何均值比0.75(95%CI 0.65–0.87,P<0.001),非奈利酮较安慰剂额外降低25%。
  • 中位尿白蛋白肌酐比:非奈利酮组从基线574.6降至6个月373.5;安慰剂组从506.4降至475.6。
  • 不良事件:最常见为高钾血症(非奈利酮组12例[10.1%] vs 安慰剂组4例[3.3%]),2例(1.7%)因高钾血症停用非奈利酮。
  • 6个月eGFR变化:非奈利酮组-5.6 ml/min/1.73m² vs 安慰剂组-2.7 ml/min/1.73m²(差值-2.9,95%CI -5.1至-0.7);洗脱期eGFR接近基线。

证据类型、等级与局限

  • 证据类型:3期随机对照试验(FINE-ONE,NCT05901831),由Bayer资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在1型糖尿病合并CKD、已用ACE抑制剂或ARB、eGFR 25至<90 ml/min/1.73m²且尿白蛋白肌酐比200至<5000的成人中,非奈利酮每日10或20 mg(依eGFR)治疗6个月可降低尿白蛋白肌酐比,但需监测高钾血症(非奈利酮组10.1% vs 安慰剂组3.3%)和eGFR下降(-5.6 vs -2.7 ml/min/1.73m²)。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown.

METHODS: We conducted a phase 3 trial involving adults who had type 1 diabetes, CKD (estimated glomerular filtration rate [eGFR], 25 to <90 ml per minute per 1.73 m2 of body-surface area), and albuminuria (urinary albumin-to-creatinine ratio [with albumin measured in milligrams and creatinine measured in grams], 200 to <5000) and were receiving an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin-receptor blocker. Participants were randomly assigned to receive finerenone (10 or 20 mg per day, depending on the eGFR) or matching placebo. The primary outcome was the relative change in the urinary albumin-to-creatinine ratio over a period of 6 months.

RESULTS: A total of 242 participants underwent randomization. The median urinary albumin-to-creatinine ratio decreased from 574.6 at baseline to 373.5 at 6 months among all the participants assigned to receive finerenone and from 506.4 to 475.6 among those assigned to receive placebo. Over a period of 6 months, the urinary albumin-to-creatinine ratio decreased by 34% with finerenone (geometric mean ratio to baseline, 0.66; 95% confidence interval [CI], 0.60 to 0.73) and 12% with placebo (geometric mean ratio to baseline, 0.88; 95% CI, 0.79 to 0.98), which corresponded to a 25% greater reduction with finerenone than with placebo (geometric mean ratio for finerenone vs. placebo, 0.75; 95% CI, 0.65 to 0.87; P<0.001). The most common adverse event was hyperkalemia (in 12 participants [10.1%] with finerenone and in 4 [3.3%] with placebo); 2 participants (1.7%) discontinued finerenone because of hyperkalemia. At 6 months, the change in the eGFR was -5.6 ml per minute per 1.73 m2 with finerenone and -2.7 ml per minute per 1.73 m2 with placebo (difference, -2.9 ml per minute per 1.73 m2; 95% CI, -5.1 to -0.7); eGFR values approached baseline levels during the washout period.

CONCLUSIONS: In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Heerspink HJL, Birkenfeld AL, Cherney DZI, et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026. PMID: 41780000. doi:10.1056/NEJMoa2512854

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。